|Brand name(s), other common name(s)||Venclexta®|
|Drug type||BCL-2 inhibitor|
|How the drug is given||By mouth|
Indications and Usage
Venetoclax is FDA approved
- For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
- In combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
This indication is approved under accelerated approval based on response rates. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Side effects needing medical attention
Neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia, and fatigue. Serious adverse reactions were pneumonia, febrile neutropenia, pyrexia (fever), autoimmune hemolytic anemia, anemia, and tumor lysis syndrome (TLS).